N4 Pharma PLC Exercise of Warrants and Total Voting Rights (2389H)
March 09 2018 - 2:43AM
UK Regulatory
TIDMN4P
RNS Number : 2389H
N4 Pharma PLC
09 March 2018
N4 Pharma Plc
("N4 Pharma" or the "Company")
Exercise of Warrants and Total Voting Rights
The Company announces that it has received an exercise notice
for the exercise of 1,878,827 warrants over ordinary shares of 0.4p
each at an exercise price of 8.5 pence per warrant ("New Ordinary
Shares"). Application has been made for admission of 1,878,827 New
Ordinary Shares to trading on AIM ("Admission") and it is expected
that Admission will take place and that trading will commence on
AIM at 8.00 a.m. on 15 March 2018.
Following Admission, there will be a total of 90,962,537
ordinary shares in issue. Shareholders should use the figure of
90,962,537 as the denominator for the calculations by which they
will determine if they are required to notify their interest in, or
a change to their interest in the Company, under the FCA's
Disclosure and Transparency Rules.
Enquiries:
N4 Pharma
CEO, Nigel Theobald Via Alma PR
Stockdale Securities
Tom Griffiths Tel: +44(0)207 601 6100
Alma PR
Josh Royston Tel: +44(0)778 090 1979
Robyn Fisher Tel: +44(0)754 070 6191
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company which
reformulates existing drugs and vaccines to improve their
performance.
N4 Pharma's reformulation work falls under two divisions:
-- generic, already commercialised, drugs; and
-- delivery of novel and existing vaccines.
N4 Pharma has identified a number of established drugs that
could be improved upon through its reformulation techniques. N4
Pharma's most advanced reformulation is for sildenafil, widely
marketed as Viagra, where N4 Pharma is seeking to improve the speed
at which the drug takes effect whilst also extending its duration
of action.
N4 Pharma's reformulation approach should take approximately
three years to obtain regulatory approval as opposed to the
traditional process for new drugs of on average ten years. The cost
and risk profile of this model is also significantly less than the
traditional process. N4 Pharma's business model for generics is to
take reformulated drugs from its portfolio through to the stage
where it will license its newly reformulated drugs to
pharmaceutical companies to commercialise them. N4 Pharma's
revenues should be derived from up front milestone and royalty
payments associated with the licence.
N4 Pharma's business model for vaccines is to undertake the
required clinical work to demonstrate the capability of its
delivery system as a cancer vaccine or therapeutic treatment so
that it can license the technology to major players developing
treatments in this area, again in return for up front milestone and
royalty payments associated with the licence.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCDMGGFRLMGRZG
(END) Dow Jones Newswires
March 09, 2018 03:43 ET (08:43 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Mar 2024 to Apr 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
From Apr 2023 to Apr 2024